N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide has been researched along with tofacitinib in 1 studies
Studies (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Trials (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Recent Studies (post-2010) (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Studies (tofacitinib) | Trials (tofacitinib) | Recent Studies (post-2010) (tofacitinib) |
---|---|---|---|---|---|
9 | 0 | 7 | 1,619 | 214 | 1,519 |
Protein | Taxonomy | N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide (IC50) | tofacitinib (IC50) |
---|---|---|---|
Chain A, Tyrosine-protein kinase | Homo sapiens (human) | 0.0117 | |
Chain A, Tyrosine-protein kinase | Homo sapiens (human) | 0.0117 | |
Chain A, Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0117 | |
Dual specificity mitogen-activated protein kinase kinase 7 | Homo sapiens (human) | 0.0815 | |
Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.2065 | |
Rho-associated protein kinase 2 | Homo sapiens (human) | 3.4 | |
Epidermal growth factor receptor | Homo sapiens (human) | 0.0815 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0815 | |
Tyrosine-protein kinase Lck | Homo sapiens (human) | 2.6933 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.015 | |
Cytochrome P450 2C8 | Homo sapiens (human) | 0.0014 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.0037 | |
Cytochrome P450 2A6 | Homo sapiens (human) | 0.012 | |
Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0575 | |
Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.1411 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.0016 | |
Tyrosine-protein kinase Tec | Homo sapiens (human) | 0.0815 | |
Tyrosine-protein kinase TXK | Homo sapiens (human) | 0.0815 | |
Tyrosine-protein kinase Blk | Homo sapiens (human) | 0.0815 | |
Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.0815 | |
Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0408 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.0006 | |
Tyrosine-protein kinase BTK | Homo sapiens (human) | 0.0815 | |
Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | 0.0815 | |
Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0815 | |
Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.0143 | |
Tyrosine-protein kinase JAK3 | Mus musculus (house mouse) | 0.664 | |
Tyrosine-protein kinase JAK2 | Rattus norvegicus (Norway rat) | 3.57 | |
Tyrosine-protein kinase JAK3 | Rattus norvegicus (Norway rat) | 1.2 | |
Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | 5.76 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide and tofacitinib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |